Shopping Cart
- Remove All
- Your shopping cart is currently empty
MeTC7 is a vitamin D receptor (VDR) antagonist with antitumor activity that inhibits PD-L1 and may inhibit the growth of xenografts and transgenic tumors in vivo.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $46 | In Stock | |
5 mg | $139 | In Stock | |
10 mg | $258 | In Stock | |
25 mg | $433 | In Stock | |
50 mg | $639 | In Stock | |
100 mg | $913 | In Stock |
Description | MeTC7 is a vitamin D receptor (VDR) antagonist with antitumor activity that inhibits PD-L1 and may inhibit the growth of xenografts and transgenic tumors in vivo. |
Targets&IC50 | VDR:2.9 μM |
In vitro | MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 shows potent VDR inhibition activity with an IC50=2.9 μM. [1] Treatment with 250 nM MeTC7 for 18 h was able to inhibit the expression of RXRα and Importin-4 and induce PARP1 cleavage, thereby inhibiting the viability of ovarian cancer cells. [1] |
In vivo | By intraperitoneal injection of 10 mg/kg MeTC7 was able to inhibit the growth of spontaneous transgenic TH-MYCN neuroblastoma and xenograft tumors in vivo. [1] |
Alias | MeTC 7 |
Molecular Weight | 618.65 |
Formula | C32H48BrN3O4 |
Cas No. | 1817841-22-7 |
Smiles | O=C1N2C34[C@@]([C@]5(C)C(N2C(=O)N1C)(C=C3)C[C@@H](OC(CBr)=O)CC5)(CC[C@@]6(C)[C@]4(CC[C@@]6([C@@H](CCCC(C)C)C)[H])[H])[H] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 10 mg/mL(16.16 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.